- Home
- Z vs VTRS Comparison
Z vs VTRS Comparison
Compare Z & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- Z
- VTRS
- Stock Information
- Founded
- Z 2004
- VTRS 1961
- Country
- Z United States
- VTRS United States
- Employees
- Z N/A
- VTRS N/A
- Industry
- Z Business Services
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- Z Consumer Discretionary
- VTRS Health Care
- Exchange
- Z Nasdaq
- VTRS Nasdaq
- Market Cap
- Z 17.0B
- VTRS 14.0B
- IPO Year
- Z 2011
- VTRS N/A
- Fundamental
- Price
- Z $77.86
- VTRS $11.30
- Analyst Decision
- Z Buy
- VTRS Hold
- Analyst Count
- Z 22
- VTRS 3
- Target Price
- Z $73.19
- VTRS $13.67
- AVG Volume (30 Days)
- Z 2.4M
- VTRS 10.6M
- Earning Date
- Z 02-11-2025
- VTRS 02-26-2025
- Dividend Yield
- Z N/A
- VTRS 4.25%
- EPS Growth
- Z N/A
- VTRS N/A
- EPS
- Z N/A
- VTRS N/A
- Revenue
- Z $2,156,000,000.00
- VTRS $15,048,500,000.00
- Revenue This Year
- Z $16.45
- VTRS N/A
- Revenue Next Year
- Z $14.30
- VTRS N/A
- P/E Ratio
- Z N/A
- VTRS N/A
- Revenue Growth
- Z 13.12
- VTRS N/A
- 52 Week Low
- Z $38.45
- VTRS $9.93
- 52 Week High
- Z $86.88
- VTRS $13.62
- Technical
- Relative Strength Index (RSI)
- Z 57.33
- VTRS 28.18
- Support Level
- Z $74.64
- VTRS $11.13
- Resistance Level
- Z $77.33
- VTRS $12.02
- Average True Range (ATR)
- Z 2.00
- VTRS 0.32
- MACD
- Z 0.30
- VTRS -0.09
- Stochastic Oscillator
- Z 93.25
- VTRS 10.97
About Z Zillow Group Inc. Class C Capital Stock
Zillow Group Inc is an Internet-based real estate company that offers its customers an on-demand experience for selling, buying, renting, or financing with transparency and ease The group works with real estate agents, brokers, builders, property managers, and landlords to pair technology with top-notch service. The group has brands such as Zillow, Trulia, StreetEasy, Hotpads, Zillow Rentals, Zillow Home Loans, ShowingTime, Follow Up Boss, Aryeo and others.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.